Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/23/2012 | 11:04am CEST

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
01:06a SIMS METAL MANAGEMENT : Becoming a substantial holder
01:01a XYZPRINTING : Announces Newly Expanded 3D Printing Product Suite on the Heels of Winning Best Choice Golden Award at COMPUTEX Taipei
01:01a GLORY GLOBAL SOLUTIONS : Announces Its Ntegra™ Plus Banknote Sorter for the Next Generation Australian Banknotes
01:01a INTREPID MINES AUSTRALIA : IAU – Final share buy-back notice – Appendix 3F – 30 May 2016
12:56a CORAL CARNAGE : take your anger to the polling booth, says Greenpeace
12:50a REDFLOW : Product & manufacturing update
12:50a SUNCORP : Appointment of Chief Information Officer
12:50a ALS : Appendix 3B - Share Rights forfeited
12:41a OOREDOO : launches fastest 1Gbps fibre plan
12:41a PACIFIC AMERICAN COAL : 25.05.2016 Successful Cash Placement Appendix 3B
Latest news
Advertisement
Hot News 
MAY 31 DEADLINE ALERT : GPM Reminds Investors of the Looming Deadline in the Class Action Lawsuit Against DS Healthcare Group, Inc.
K&C REIT : Sells Newbury, Berkshire Retail Site For GBP210,000
VOLVERE : Sees Profits Rise In 2015, Boosted By Shire Foods Sales
PURICORE : To Stop Selling ProduceFresh Until Registered As Pesticide
UBISENSE : Notice of AGM
Most Read News
06:56p CORAL CARNAGE : take your anger to the polling booth, says Greenpeace
07:01p INTREPID MINES AUSTRALIA : IAU – Final share buy-back notice – Appendix 3F – 30 May 2016
06:41p PACIFIC AMERICAN COAL : 25.05.2016 Successful Cash Placement Appendix 3B
06:50p SUNCORP : Appointment of Chief Information Officer
06:50p ALS : Appendix 3B - Share Rights forfeited
Most recommended articles
05:30pDJSUNCOR ENERGY : Starts to Bring Canadian Oil Sands Back Online
05:21p SUNCOR ENERGY : ramping up operations after Canada wildfire
12:22pDJVOLKSWAGEN : 1Q 2016 - Forecast
11:16a BPOST : Belgian, Dutch mail firms to confirm merger talks on Monday-Le Soir
09:56a GEORG FISCHER : Switzerland's Fischer grooms CEO candidates - SonntagsZeitung